Lv55
1040 积分 2025-03-30 加入
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
1个月前
已完结
French NOMADMUS Cohort Overview
1个月前
已完结
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD
3个月前
已完结
Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
3个月前
已关闭
Nucleic Acid Programmable Protein Arrays for Autoantibody Discovery: A Step-by-Step Guide
4个月前
已完结
Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients
5个月前
已完结
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Mechanisms, Syndromes, and Management
6个月前
已完结
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial
6个月前
已完结
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study
6个月前
已完结
Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD
6个月前
已完结
皖公网安备34019202002308
